NYSE:TEVAPharmaceuticals
Teva (TEVA) Is Up 9.1% After AJOVY Wins FDA Approval for Pediatric Migraine Prevention
Earlier this month, Teva Pharmaceutical Industries announced that the U.S. FDA has approved AJOVY for the preventive treatment of episodic migraine in children and adolescents aged 6-17 years weighing at least 45 kilograms, making it the first and only CGRP antagonist approved for this pediatric population.
This regulatory milestone expands AJOVY's market reach and addresses an unmet need in pediatric migraine prevention, reinforcing Teva's position in neuroscience therapies.
We'll assess...